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Global cellular regulation including cardiac function by post-translational protein
arginylation
In this issue a very significant contribution to cardiology describing critical roles of
ATE1 appeared (Kurosaka et al). In view of this paper, we have been asked to
contribute an article (editorial) regarding ATE1(enzyme which transfers arginine from
arginyl tRNA to protein acceptors). This short article consists of three sections: 1) a
historical anecdote describing how ATE1 was discovered; 2) its possible role in aging
and cellular transformation; 3) most importantly, its role in the development and
maintenance of cardiac activity. The last section has direct bearing to the Kurosaka et al
paper.
In 1962, during the course of studying cell free protein synthesis by an E. coli extract
at Oak Ridge National Laboratory, one of the leading Institutes for studies on protein
synthesis at that time, we forgot to add ribosomes to one of the test tubes. To our great
surprise, C14-labeled phenylalanine and leucine were incorporated into hot trichloro
acetic acid (TCA) insoluble fraction, almost to the same extent as those with ribosomes!
At that time, incorporation of C14-labeled phenylalanine and leucine into acid-insoluble
fraction was assumed to represent de novo protein synthesis. Normally, one would do
this kind of control without ribosomes, but we did not do this control because nobody
ever imagined “protein synthesis” without ribosomes. This finding that “protein
synthesis” occurs in the absence of ribosomes was therefore unbelievable. Of course,
the extract (soluble fraction) itself has been subjected to conventional high speed
centrifugation, which had been established to remove ribosomes.
To convince ourselves and the entire laboratory, we carried out all possible
experiments to examine possible residual ribosomes that could be responsible for this
unexpected observation. First, the use of Model E analytical centrifuge (now found only
in museums) revealed no ribosomal band. One can see the ribosome band during
centrifugation with the Model E centrifuge and was used to obtain the sedimentation
coefficient. Next, we examined the extract by electron microscope to look for any
ribosome-like particles. No particulate components were visible under the microscope.
We then fractionated the “ribosome-free” extract on sucrose gradient centrifugation, a
technique considered as one of the most advanced and fashionable, at that time. The
determination of the peak of amino acids incorporating activity in the extract and amino
acids incorporated by the extract turned out to be sedimenting at the position
corresponding to 10S. This was far lower than 70S particles (ribosome). Therefore, this
system was named, “A Soluble Amino Acid Incorporating System” [1]. We then checked
if amino acids other than phenylalanine or leucine could be incorporated. At this point,
we had the second surprise. Amino acids other than phenylalanine or leucine were
incorporated only nominally [2, 3]. When we arrived at Oak Ridge, there were about 20
postdoctoral fellows working on protein synthesis. Most of them were studying
incorporation of C14 phenylalanine or leucine into acid-insoluble material. We asked why
these amino acids were studied, and the answer was “because you get more
incorporation!”
There was another reason why everybody in the lab believed that the C14
phenylalanine and leucine incorporation being studied must represent “protein

synthesis”. At that time, it was well accepted that the addition of RNA polymerase and
DNA should increase the in vitro synthesis of protein. Naturally, in attempts to increase
“protein synthesis”, we added DNA and crude partially purified RNA polymerase. As
expected, the incorporation of C14 phenylalanine or leucine went up significantly upon
the addition of partially purified RNA polymerase. This added credibility to the belief that
the incorporation of C14 phenylalanine or leucine, indeed, represents protein synthesis.
After we were convinced that the incorporation does not represent protein synthesis, we
examined the partially purified RNA polymerase (protamine precipitate) and found that
this fraction had a very high activity of the amino acid incorporation into the acidinsoluble material without ribosomes. After this discovery, we determined that the
incorporated C14 phenylalanine and leucine represent the addition to the preexisting
protein and is not internally incorporated [2-4]. The proteins responsible for the transfer
of leucine and/or phenylalanine were named later as leucyl or phenylalanyl tRNA
protein transferase (L/F-transferase). Although the crystal structure of the enzyme has
been elucidated and the function appears to give the signal for protein degradation [5],
the enzyme does not appear to be essential for E. coli survival.
Because of this unexpected finding with the E. coli extract, we examined if a
similar phenomena could be seen in higher organisms. As in prokaryotic L/F-transferase
the ribosome-free supernatant of rat liver homogenate was prepared after 100,000xg
centrifugation. To our surprise, the major radioactive amino acid to be incorporated by
the extract devoid of ribosome was arginine, and no significant incorporation of other
radioactive amino acids was found [6]. The enzyme responsible for this transfer of
arginine from arginyl tRNA to protein fraction was termed arginyl tRNA protein
transferase (ATE1). This is an enzyme identified as capable of modifying proteins at the
post-translational level. It functions by covalently binding arginine to the amino-terminus
of acceptor proteins with acidic amino acids residues as well as side chains on different
sites [7, 8]. ATE1 activity is, of course, dependent upon the cell's ability to form arginyltRNA, via arginyl-tRNA synthetase. ATE1 has been isolated from yeast [9], various
animal tissues and cell cultures [10-12]. It has been shown to modify in vitro bovine
thyroglobulin, angiotensin II and beta-melanocyte-stimulating hormone [12, 13].
Additionally, ATE1 modifies some of chromosomal histones, non-histone proteins [14],
and membrane proteins [15]. Those exogenously added acceptor proteins that have
been modified in vitro by the enzyme are found to contain aspartic or glutamic acid at
the amino terminus, thus conferring a degree of specificity to arginine transfer [16].
Although the precise physiological function of ATE1 was not known then, we postulated
that the system is closely associated with cell regulatory and/or proliferative functions,
perhaps acting as a "switching" mechanism to activate or inactivate particular cellular
proteins. In support of this theory were the observations that transferase activity is
significantly increased in regenerating rat liver and ascites tumor cells [17]. Normal rat
kidney cells transformed by Rous sarcoma virus [18], rat embryo cells transformed by
dimethyl benzanthracene (carcinogen) [19] had increased transferase activity. In
contrast, transferase activity decreased upon aging of human cultured cells as shown
by Kaji et al in 1980 [20]. This leads to the second section dealing with the role of ATE1
in aging.

Human fibroblast strains IMR90 and WI38 have a finite life span and provide
model systems for studying cellular aging. In contrast to these normal fibroblasts, SV40transformed cells do not exhibit aging phenomena. We have examined the population
doubling time, protein concentration, ATE1 and ATE1-directed modification of
chromosomal proteins in non-transformed and SV40 virus-transformed cells [20, 21]. It
was found that the population doubling time and cellular protein content increase as the
cells enter cellular senescence, whereas the total activity of ATE1 and the ability of
chromosomal proteins to accept arginine at the amino-terminal end diminished
progressively during this period. Furthermore, the level of ATE1, which is associated
with cellular aging in non-transformed cells, remained fixed at the amount that existed
when the cells were exposed to SV40 viruses. In other words, the relative age of the
culture at which SV40 transformation occurred can be revealed by the level of ATE1,
because fixation of the age-associated parameter (the level of ATE1) occurs upon
transformation. The transformed cells are then refractory to any subsequent aging
phenomena. At the time of this discovery, we played a game of guessing the age at
which stage human fibroblast cells were transformed by SV40. We gave five different
transformed human fibroblast cell lines to a graduate student and asked him to
determine the age at which the transformation took place. We, of course, knew at which
stage the SV40 transformation occurred for each strain. It was an amazing experience
for us when our graduate student identified the cellular age at which the transformation
took place by measuring the amount of the ATE1 of these transformed human
fibroblasts! [20]. It will be an exciting project to elucidate the precise biological
significance of the decrease of ATE1 level with aging.
This finding suggested a close relationship between ATE1 and cell doubling time.
Indeed, as mentioned before, this was first observed in regenerating rat liver and
ascites tumor cells [17] in which a marked increase in the enzyme activity was evident
with regeneration or with tumor cells. Subsequent work has shown a consistent, but not
universal, relationship between cellular proliferative activity and ATE1 activity [18, 19,
22]. Aging, which is manifested as a general decrease in functional and proliferative
capacity, produced a significant decline in ATE1 activity in kidney- and liver-soluble
fractions derived from rats ranging in age from 2 weeks to 30 months [21]. The
qualitative effect in both tissues was similar in the substrate-saturated state although the
level of ATE1 in the liver preparation was quantitatively lower than that in the kidney. Of
particular interest was the magnitude of the alterations in the enzyme activity, which
suggests that if ATE1 can modulate protein function, the enzyme activity once again
may reflect the divisional capacity of a specific tissue [21].
In view of the relatively large amounts of ATE1 within the brain, it is likely that the
enzyme plays an important role in the brain [23]. However, to our surprise, neither the
acceptor proteins nor ATE1 itself are affected by the aging process [21]. The exact
physiological function of ATE1 cannot be accurately determined until specific
endogenous acceptor proteins have been identified. Further studies of ATE1 in the
brain such as Alzheimer patients’ may yield some clues to this horrible disease.
The modification of chromosomal proteins [14] by the enzyme did not correlate
with the level of cytoplasmic ATE1 activity, although distinct relationships between the
amount of the enzyme and the age were apparent [21]. The alterations in chromosomal
protein acceptor capacity in organs other than the brain are unique to the tissue in

question, and the variation in responses to the age was probably due to the diversity of
chromosomal proteins that may be altered during aging. The modification of
chromosomal proteins, specifically non-histone proteins, is of particular interest since
they are thought to play key roles in the expression of aging phenomena. At the least,
the observed changes in chromatin acceptor capacity by aging indicate the degree of
chromatin restructuring or synthesis of new proteins associated with cellular
senescence.
One of the reasons why we did not pursue the L/P transferase was that they
were not essential [24]. Having been brought up in the age where we are taught that
anything not essential is not very important, we felt that the enzyme was not worth
pursuing further. Similarly, Varshavsky’s work indicating that yeast ATE1 is not essential
[25] dampened our enthusiasm to work on this enzyme despite many interesting
features of yeast ATE1. However, our intuition guided us to work on the various aspects
of the possible role of ATE1 in higher eukaryotes, despite the fact that essentiality was
not established at that time. This intuition turned out to be correct, and arginylation is
now well accepted to be just as important as the phosphorylation [26, 27]. The very first
work, which clearly established the essential nature of ATE1 in mammals, is the
experiment where the ATE1 gene was knocked out in mice, causing lethality due to
heart defects in cardiovascular development and angiogenic remodeling during
embryogenesis [28]. Their studies revealed that in the knockout mice, abnormal cardiac
morphogenesis occurred. The underdeveloped heart had thin myocardium with
immature septa. They also observed non-separation of the aorta and pulmonary artery.
This is known as persistent truncus arteriosus. In other words, the authors discovered
that knocking out Ate1 led to the defects in cardiac contractility, myofibril development,
and death of the embryo. ATE1 is essential! These defects became more prominent at
later stages of embryonic development. However, it is unclear whether they arise
through impairments in tissue signaling and/or are secondary to the onset of the
embryonic lethality leading to the heart muscle disintegration. Following this finding, Rai
et al [7] investigated the role of arginylation in the development and function of cardiac
myocytes and their actin-containing structures during embryogenesis. They found that
alpha cardiac actin undergoes arginylation at four sites during development. These
findings indicate a new function of arginylation in the regulation of the actin cytoskeleton
in cardiac myocytes.
The paper by Kurosaka et al in this issue together with the paper discussed
above give a quantum jump to the knock-out approach, which has been used in the
studies of the physiological role of ATE1. In this paper, the authors used a unique
approach of knocking out only cardiac myofibril specific Ate1. The result was
remarkable in that these mice, termed alpha MHC-Ate1, survived to be born as
seemingly normal mice. However, the life spans of the knockout mice are much less
than those of normal mice. These mice died from complications with cardiomyopathy
and thrombosis after developing cardiac contractility defects in myofibril. The fact that
the lack of ATE1 makes the cells “age” in cardiac contractility and other characteristics,
fits to the general theme between the level of ATE1 and age as we discussed in the
preceding section. Of particular importance is that this paper clearly establishes that the
heart defect caused by the lack of ATE1 is not the secondary effect of general effect on

the development of whole mouse. The data indicate that essential nature of arginylation
for maintaining the heart function by regulation of the major myofibril proteins and
forces. Absence of ATE1 in the heart muscle leads to progressive heart failure through
cardiomyocyte-specific defects.
Of particular interest is the fact that the finding may give some clues to the agerelated heart failure of humans. A large number of “death due to age” can be ascribed to
age-related heart failure. The close relationship between the cellular aging and ATE1 as
described above and the current finding of Kurosaka et al may strongly suggest the
need for the thorough investigation on the possible relationship between ATE1 and
human heart dysfunction due to senescence.
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